share_log

10-Q: Q1 2024 Earnings Report

10-Q: Q1 2024 Earnings Report

10-Q:2024财年一季报
美股SEC公告 ·  2024/06/29 04:58

Moomoo AI 已提取核心信息

FOXO Technologies reported Q1 2024 financial results with total revenue of $7,000 and a net loss of $1.5 million, showing significant improvement from a $7.6 million loss in Q1 2023. Operating expenses decreased 84% to $1.2 million, driven by lower employee costs and reduced consulting fees.The company entered into strategic agreements, including a license agreement with KR8 AI Inc. to develop a Direct-to-Consumer app combining AI technology with FOXO's epigenetic biomarker platform. Additionally, FOXO signed stock exchange agreements with Rennova Health to acquire Myrtle Recovery Centers and Big South Fork Medical Center to enhance its business portfolio.As of March 31, 2024, FOXO had $3,000 in cash and a working capital deficit of $16.8 million. The company secured additional financing through promissory notes and entered into a Securities Purchase Agreement in June 2024 for up to $2.8 million in senior notes to support operations. Management continues to pursue strategic initiatives and capital raising efforts to address liquidity needs.
FOXO Technologies reported Q1 2024 financial results with total revenue of $7,000 and a net loss of $1.5 million, showing significant improvement from a $7.6 million loss in Q1 2023. Operating expenses decreased 84% to $1.2 million, driven by lower employee costs and reduced consulting fees.The company entered into strategic agreements, including a license agreement with KR8 AI Inc. to develop a Direct-to-Consumer app combining AI technology with FOXO's epigenetic biomarker platform. Additionally, FOXO signed stock exchange agreements with Rennova Health to acquire Myrtle Recovery Centers and Big South Fork Medical Center to enhance its business portfolio.As of March 31, 2024, FOXO had $3,000 in cash and a working capital deficit of $16.8 million. The company secured additional financing through promissory notes and entered into a Securities Purchase Agreement in June 2024 for up to $2.8 million in senior notes to support operations. Management continues to pursue strategic initiatives and capital raising efforts to address liquidity needs.
FOXO 科技公司报告了截至 2024 年 3 月 31 日的财务业绩,总收入为 7 美元,较去年同期的 13 美元有所下降。该公司净亏损为 1,504 美元,较上一年同期的净亏损 7,639 美元有所改善。减少的净亏损主要是由于营业费用的下降,从 7,405 美元降至 1,186 美元,这是由于研发成本、管理持续股票计划支出和销售、一般和行政支出的降低推动的。非营业性支出由于利息费用增加而略有增加。公司还认定了一项 656 美元的股票期权的视为股息。FOXO 科技公司继续专注于商业化表观遗传标志物科技,暂停销售新的寿险产品以保护现金。公司的流动性地位仍然令人关注,截至 2024 年 3 月 31 日,现金及现金等价物为 3 美元,并正在努力获得额外资金支持。公司未来的计划包括追求战略收购,例如提议收购 Rennova 社区健康公司,该收购预计将提供正面的营业性现金流,但无法保证交易完成或成功。
FOXO 科技公司报告了截至 2024 年 3 月 31 日的财务业绩,总收入为 7 美元,较去年同期的 13 美元有所下降。该公司净亏损为 1,504 美元,较上一年同期的净亏损 7,639 美元有所改善。减少的净亏损主要是由于营业费用的下降,从 7,405 美元降至 1,186 美元,这是由于研发成本、管理持续股票计划支出和销售、一般和行政支出的降低推动的。非营业性支出由于利息费用增加而略有增加。公司还认定了一项 656 美元的股票期权的视为股息。FOXO 科技公司继续专注于商业化表观遗传标志物科技,暂停销售新的寿险产品以保护现金。公司的流动性地位仍然令人关注,截至 2024 年 3 月 31 日,现金及现金等价物为 3 美元,并正在努力获得额外资金支持。公司未来的计划包括追求战略收购,例如提议收购 Rennova 社区健康公司,该收购预计将提供正面的营业性现金流,但无法保证交易完成或成功。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息